Factor Xa Inhibitors Concept

subject area of

• 2 Mechanisms of action of low molecular weight heparins and heparinoids  Journal Articles
• 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Journal Articles
• 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer  Journal Articles
• 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants  Journal Articles
• 4 Clinical potential of low molecular weight heparins  Journal Articles
• A Replacement for Warfarin  Journal Articles
• A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system  Journal Articles
• A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery  Journal Articles
• A hybrid automated event adjudication system for clinical trials  Journal Articles
• A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist.  Journal Articles
• A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury  Journal Articles
• A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation  Journal Articles
• A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers  Journal Articles
• A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin  Journal Articles
• A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study  Journal Articles
• A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)  Journal Articles
• A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)  Journal Articles
• A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer  Journal Articles
• Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.  Journal Articles
• Accumulating data on rivaroxaban for venous thromboembolism in clinical practice  Journal Articles
• Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial  Journal Articles
• Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors  Journal Articles
• Acute management of bleeding in patients on novel oral anticoagulants  Journal Articles
• Advances in Antithrombotic Therapy: Novel Agents  Journal Articles
• Advances in the management of venous thromboembolism  Journal Articles
• Advances in the management of venous thromboembolism.  Journal Articles
• Advantages and limitations of the new anticoagulants  Journal Articles
• Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper  Journal Articles
• An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition  Journal Articles
• An assay to measure levels of factor Xa inhibitors in blood and plasma  Journal Articles
• An overview of clinical trials of low molecular weight heparin fractions.  Journal Articles
• Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study  Journal Articles
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Journal Articles
• Andexanet Alfa for Factor Xa Inhibitor Reversal  Journal Articles
• Andexanet Alfa for Reversal of Factor Xa Inhibitors: A Critical Review of the Evidence  Journal Articles
• Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban  Journal Articles
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity  Journal Articles
• Andexanet alfa for the treatment of hemorrhage  Journal Articles
• Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis  Journal Articles
• Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC  Journal Articles
• Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. Reply.  Journal Articles
• Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage  Journal Articles
• Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients  Journal Articles
• Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?  Journal Articles
• Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849)  Journal Articles
• Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis  Journal Articles
• Anticoagulants in heart disease: current status and perspectives  Journal Articles
• Anticoagulation Therapy in Children  Journal Articles
• Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes  Journal Articles
• Anticoagulation for Mechanical Heart Valves  Journal Articles
• Antithrombotic Agents  Journal Articles
• Antithrombotic Therapy in Neonates and Children  Journal Articles
• Apixaban for Extended Treatment of Venous Thromboembolism  Journal Articles
• Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review  Journal Articles
• Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation  Journal Articles
• Apixaban in Acute Coronary Syndromes  Journal Articles
• Apixaban in Patients with Atrial Fibrillation  Journal Articles
• Apixaban to Prevent Venous Thromboembolism in Patients with Cancer  Journal Articles
• Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement  Journal Articles
• Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.  Journal Articles
• Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation  Journal Articles
• Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study.  Journal Articles
• Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome  Journal Articles
• Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials  Journal Articles
• Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty  Journal Articles
• Assays for Measuring Rivaroxaban: Their Suitability and Limitations  Journal Articles
• Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes  Journal Articles
• Barriers and facilitators to optimal oral anticoagulant management: a scoping review  Journal Articles
• Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin  Journal Articles
• Beyond Unfractionated Heparin and Warfarin  Journal Articles
• Bilateral paramedian pontine infarcts: a rare cause of bilateral horizontal gaze palsy  Journal Articles
• Bleeding Complications and Management on anticoagulant therapy  Journal Articles
• Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design  Journal Articles
• Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery  Journal Articles
• COMPASS for Vascular Surgeons  Journal Articles
• Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48  Journal Articles
• Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF  Journal Articles
• Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS  Journal Articles
• Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial  Journal Articles
• Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source  Journal Articles
• Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial  Journal Articles
• Choosing the optimal oral anticoagulant for stroke prevention in atrial fibrillation: direct oral anticoagulants vs vitamin K antagonists.  Journal Articles
• Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials  Journal Articles
• Circulating heparin‐like anticoagulants: Case report and review of literature  Journal Articles
• Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study  Journal Articles
• Clinical Implications of Reversal Agents for Direct Oral Anticoagulants  Journal Articles
• Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.  Conferences
• Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist  Journal Articles
• Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients  Journal Articles
• Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis  Journal Articles
• Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study  Journal Articles
• Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?  Journal Articles
• Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.  Journal Articles
• Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study  Journal Articles
• Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy  Journal Articles
• Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)  Journal Articles
• Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial  Journal Articles
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents  Journal Articles
• DOACs: role of anti-Xa and drug level monitoring.  Journal Articles
• Dabigatran: ready for prime time?  Journal Articles
• Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency  Journal Articles
• Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH  Journal Articles
• Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy  Journal Articles
• Design of the rivaroxaban for heparin-induced thrombocytopenia study  Journal Articles
• Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation  Journal Articles
• Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.  Journal Articles
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies  Journal Articles
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials  Journal Articles
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Journal Articles
• Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis  Journal Articles
• Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.  Journal Articles
• Direct oral anticoagulants: evidence and unresolved issues  Journal Articles
• Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism  Journal Articles
• Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events  Journal Articles
• Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease  Journal Articles
• Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves  Journal Articles
• Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer  Journal Articles
• Edoxaban for treatment of venous thromboembolism in patients with cancer  Journal Articles
• Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial  Journal Articles
• Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial  Journal Articles
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty  Journal Articles
• Effect of Peripheral Interventions in Patients with Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses from the XATOA Registry  Journal Articles
• Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study  Journal Articles
• Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism  Journal Articles
• Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state  Journal Articles
• Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism  Journal Articles
• Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1  Journal Articles
• Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial  Journal Articles
• Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial  Journal Articles
• Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease  Journal Articles
• Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction  Journal Articles
• Evaluation of the MRX PT DOAC assay for detection of clinically relevant factor Xa inhibitor drug levels.  Journal Articles
• Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin  Journal Articles
• Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients  Journal Articles
• Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study  Journal Articles
• External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry  Journal Articles
• External applicability of the COMPASS trial: the Western Denmark Heart Registry  Journal Articles
• FRAIL-AF Study: More Bleeding With DOACs Compared With VKAs in Patients With Frailty?  Journal Articles
• Factor XI Inhibition to Uncouple Thrombosis From Hemostasis  Journal Articles
• Factor Xa and thrombin as targets for new oral anticoagulants  Journal Articles
• Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism  Journal Articles
• Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors  Journal Articles
• Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur  Journal Articles
• Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6  Journal Articles
• Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin  Journal Articles
• Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy  Journal Articles
• Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial  Journal Articles
• Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source  Journal Articles
• Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors  Journal Articles
• Gastrointestinal Bleeding With Edoxaban Versus Warfarin  Journal Articles
• Global Prospective Safety Analysis of Rivaroxaban  Journal Articles
• Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors  Journal Articles
• Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease  Journal Articles
• Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding  Journal Articles
• Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE  Journal Articles
• High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source  Journal Articles
• How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?  Journal Articles
• How can we reverse bleeding in patients on direct oral anticoagulants?  Journal Articles
• How to use unfractionated heparin to treat neonatal thrombosis in clinical practice  Journal Articles
• Identifying and Treating Young Patients at Risk for Cardiovascular Events  Journal Articles
• Identifying the highest risk vascular patients: Insights from the XATOA registry  Journal Articles
• Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial  Journal Articles
• Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban  Journal Articles
• Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE  Journal Articles
• Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial  Journal Articles
• Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy  Journal Articles
• Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study  Journal Articles
• In DVT, oral DTIs and factor Xa inhibitors reduce major bleeding but not recurrent VTE vs. conventional anticoagulants  Journal Articles
• In acute ischemic stroke with AF, early DOAC initiation was noninferior to delayed initiation for ischemic and hemorrhagic outcomes at 90 d.  Journal Articles
• Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial  Journal Articles
• Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta‐analysis of prospective studies  Journal Articles
• Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation  Journal Articles
• Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome  Journal Articles
• Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes  Journal Articles
• Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery  Journal Articles
• Inhibition of Fibrin-Bound Thrombin by a Covalent Antithrombin-Heparin Complex  Journal Articles
• Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex  Journal Articles
• Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome  Journal Articles
• Interaction of low molecular weight heparin with ketorolac  Journal Articles
• Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy  Journal Articles
• Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex  Journal Articles
• Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48  Journal Articles
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Journal Articles
• Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation  Journal Articles
• Laboratory monitoring of low‐molecular‐weight heparin therapy  Journal Articles
• Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin  Journal Articles
• Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial  Journal Articles
• Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES  Journal Articles
• Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels  Journal Articles
• Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD  Journal Articles
• Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.  Journal Articles
• Low-dose Rivaroxaban Plus Aspirin for the Prevention of Cardiovascular Events: an Evaluation of COMPASS  Journal Articles
• Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials  Journal Articles
• Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial  Journal Articles
• Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review  Journal Articles
• Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study  Journal Articles
• Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease  Journal Articles
• Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin  Journal Articles
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Journal Articles
• Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms  Journal Articles
• Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis  Journal Articles
• Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex  Journal Articles
• Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex  Journal Articles
• Meeting the Unmet Needs in Anticoagulant Therapy  Journal Articles
• Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.  Journal Articles
• Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate?  Journal Articles
• Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease  Journal Articles
• Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials  Journal Articles
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Journal Articles
• Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy  Journal Articles
• New Anticoagulants for Atrial Fibrillation  Journal Articles
• New Antithrombotic Drugs: Potential for Use in Oncology  Journal Articles
• New aspects on treatment modalities for thromboembolic episodes  Journal Articles
• New oral anticoagulants in atrial fibrillation  Journal Articles
• New oral anticoagulants in development  Journal Articles
• New oral anticoagulants: not quite there yet  Journal Articles
• New oral anticoagulants: which one should my patient use?  Journal Articles
• New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010  Journal Articles
• News at XI: moving beyond factor Xa inhibitors  Journal Articles
• Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke  Journal Articles
• North America anticoagulation forum guidance on reversal of direct oral anticoagulants  Journal Articles
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Journal Articles
• Novel oral anticoagulants and reversal agents: Considerations for clinical development  Journal Articles
• Novel paediatric anticoagulants: a review of the current literature  Journal Articles
• Oral Anticoagulant Therapy  Journal Articles
• Oral Apixaban for the Treatment of Acute Venous Thromboembolism  Journal Articles
• Oral Direct Factor Xa Inhibitors  Journal Articles
• Oral Rivaroxaban for Symptomatic Venous Thromboembolism  Journal Articles
• Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial  Journal Articles
• Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis  Journal Articles
• Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement  Journal Articles
• Oral factor Xa inhibitors and risk of subdural hematoma  Journal Articles
• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement  Journal Articles
• Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases  Journal Articles
• Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials  Journal Articles
• Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study  Journal Articles
• Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation  Journal Articles
• Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study  Journal Articles
• Overview of the New Oral Anticoagulants  Journal Articles
• Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry  Journal Articles
• Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS ₂ Score: Insights From the BRAIN-AF Trial  Journal Articles
• Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice  Journal Articles
• Pentasaccharides  Journal Articles
• Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial  Journal Articles
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Journal Articles
• Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients  Conferences
• Pharmacologic tools to reduce bleeding in surgery.  Journal Articles
• Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome  Journal Articles
• Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose  Journal Articles
• Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment  Journal Articles
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery  Journal Articles
• Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients  Journal Articles
• Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study  Journal Articles
• Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants  Journal Articles
• Preclinical differentiation of low molecular weight heparins.  Journal Articles
• Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study  Journal Articles
• Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial  Journal Articles
• Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial  Journal Articles
• Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2)  Journal Articles
• Probable fondaparinux-associated bullous hemorrhagic dermatosis  Journal Articles
• Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study  Journal Articles
• Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism  Journal Articles
• Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins  Journal Articles
• Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent  Journal Articles
• Protein adsorption on polyurethane catheters modified with a novel antithrombin‐heparin covalent complex  Journal Articles
• Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study  Journal Articles
• Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors  Journal Articles
• Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery.  Journal Articles
• Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors  Journal Articles
• Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study  Journal Articles
• RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome  Journal Articles
• Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation  Journal Articles
• Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis  Journal Articles
• Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention  Journal Articles
• Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)  Journal Articles
• Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial  Journal Articles
• Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS  Journal Articles
• Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation  Journal Articles
• Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation  Journal Articles
• Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study  Journal Articles
• Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins  Journal Articles
• Reply  Journal Articles
• Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban  Journal Articles
• Response to “Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban”  Journal Articles
• Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients  Journal Articles
• Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches  Journal Articles
• Reversal agents for current and forthcoming direct oral anticoagulants  Journal Articles
• Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH  Journal Articles
• Reversing Anticoagulant Therapy  Journal Articles
• Review: In renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants  Journal Articles
• Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial  Journal Articles
• Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban  Journal Articles
• Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants  Journal Articles
• Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.  Journal Articles
• Risk of recurrent venous thromboembolism according to baseline risk factor profiles  Journal Articles
• Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis  Journal Articles
• Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial  Journal Articles
• Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial  Journal Articles
• Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial  Journal Articles
• Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease  Journal Articles
• Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease  Journal Articles
• Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization  Journal Articles
• Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios  Journal Articles
• Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation  Journal Articles
• Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro  Journal Articles
• Rivaroxaban for Patients with Intermittent Claudication.  Journal Articles
• Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial  Journal Articles
• Rivaroxaban for Prevention and Treatment of Venous Thromboembolism  Journal Articles
• Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline  Journal Articles
• Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source  Journal Articles
• Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness  Journal Articles
• Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer  Journal Articles
• Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease  Journal Articles
• Rivaroxaban for treatment of HIT: A riveting first experience  Journal Articles
• Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study  Journal Articles
• Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment  Journal Articles
• Rivaroxaban in Peripheral Artery Disease after Revascularization  Journal Articles
• Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation  Journal Articles
• Rivaroxaban in Stable Cardiovascular Disease  Journal Articles
• Rivaroxaban in treatment refractory heparin-induced thrombocytopenia  Journal Articles
• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism  Journal Articles
• Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial  Journal Articles
• Rivaroxaban plus aspirin after lower-extremity revascularization.  Journal Articles
• Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition  Journal Articles
• Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers  Journal Articles
• Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty  Journal Articles
• Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy  Journal Articles
• Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial  Journal Articles
• Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial  Journal Articles
• Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study  Journal Articles
• Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial  Journal Articles
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease  Journal Articles
• Rivaroxaban with or without aspirin for prevention of cardiovascular disease  Journal Articles
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial  Journal Articles
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  Journal Articles
• Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion  Journal Articles
• Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease.  Journal Articles
• Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease  Journal Articles
• SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery  Journal Articles
• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin  Journal Articles
• Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation  Journal Articles
• Selective factor Xa inhibition for thromboprophylaxis  Journal Articles
• Setting a standard for venous thromboembolism prophylaxis  Journal Articles
• Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustment  Journal Articles
• Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation  Journal Articles
• Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease  Journal Articles
• The APTT Response of Pregnant Plasma to Unfractionated Heparin  Journal Articles
• The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective  Journal Articles
• The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis  Journal Articles
• The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation  Journal Articles
• The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?  Journal Articles
• The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE  Journal Articles
• The Real Decoy  Journal Articles
• The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement  Journal Articles
• The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation  Journal Articles
• The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig  Journal Articles
• The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial  Journal Articles
• The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study  Journal Articles
• The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era  Journal Articles
• The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect  Journal Articles
• The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial  Journal Articles
• The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients  Journal Articles
• The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin.  Journal Articles
• The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants  Journal Articles
• Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin  Journal Articles
• Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively  Journal Articles
• To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment  Journal Articles
• Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial  Journal Articles
• Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial  Journal Articles
• Total intracranial hemorrhage volume measurement summating all compartments best in traumatic and nontraumatic intracranial bleeding  Journal Articles
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Journal Articles
• Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies  Journal Articles
• Treatment of bleeding complications in patients on anticoagulant therapy  Journal Articles
• Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti‐factor Xa levels  Journal Articles
• Unresolved issues in the use of direct acting oral anticoagulants  Journal Articles
• Urgent Need to Measure Effects of Direct Oral Anticoagulants  Journal Articles
• Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children  Journal Articles
• Use of selective factor Xa inhibitors in special populations.  Journal Articles
• Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study  Journal Articles
• Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation  Journal Articles
• What Is the Future of Factor XI Inhibitors?  Journal Articles
• Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?  Journal Articles
• XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America  Journal Articles
• XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation  Journal Articles
• XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation  Journal Articles
• Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both  Journal Articles